This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06769425 as recruiting, last updated 2025-06-24. Enrolment is 157 planned participants, an estimate. Interventions: HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib, HS-10502 + HS-20089, HS-10502 + Platinum + Bevacizumab, HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan, HS-10502 + Bevacizumab. Primary measures include Maximum tolerated dose (MTD) of HS-10502(Stage 1:Dose escalating stage); Maximum applicable dose (MAD) of HS-10502(Stage 1:Dose escalating stage). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-08. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HS-10502, PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types), Prostate cancer.
Shares PARP, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types), Prostate cancer.
Shares PARP, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/